K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
4 clinical trials · Sponsor
◉ Watch K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
| Record | Firm | Date |
|---|---|---|
| Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) (NCT05682170) | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | 2022-12-01 |
| Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis (NCT05199337) | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | 2021-11-30 |
| A Food Effect Study of ZN-d5 in Healthy Female Volunteers (NCT04854174) | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | 2021-06-13 |
| Phase 1 First in Human Study of ZN-d5 as a Single Agent (NCT04500587) | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | 2020-10-13 |
Track K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.